Axsome Therapeutics, Inc. (AXSM) Stock Forecast
AXSM analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.77 / 5 from 22 analysts
- Price target
- $282.54 average of analyst targets
- Upside to target
- +79.8% from the latest close
- Next earnings
- November 2, 2026 EPS estimate $-0.65
- 52-week range
- $127.06 – $255.17
AXSM analyst ratings
22 analystsNumber of analysts at each rating.
AXSM price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
AXSM earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.63 | −$1.00 | −$0.41 | −$0.94 | +33.3% | 13 |
| Current fiscal year (2026) | −$2.98 | −$3.79 | −$2.28 | −$3.47 | +14.3% | 13 |
| Next fiscal year (2027) | $4.04 | $0.37 | $7.83 | −$2.98 | +235.7% | 12 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
AXSM revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $250.9M | $227.9M | $262.2M | +46.7% | 20 |
| Current fiscal year (2026) | $952.6M | $874.6M | $991.7M | +49.2% | 21 |
| Next fiscal year (2027) | $1.52B | $1.33B | $1.75B | +59.4% | 20 |
AXSM EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
AXSM revenue: reported and forecast
AXSM EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.34 | −$0.46 | −$0.46 | −$0.52 | −$0.63 | +82.9% | 0 up · 3 down |
| Current fiscal year (2026) | −$1.70 | −$2.64 | −$2.64 | −$2.72 | −$2.98 | +75.1% | 0 up · 2 down |
| Next fiscal year (2027) | $5.88 | $5.03 | $5.03 | $4.70 | $4.04 | −31.3% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
AXSM earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; AXSM beat in 5 of 12.
What analysts expect from AXSM
22 analysts cover Axsome Therapeutics; their consensus rating is strong buy (4.77 on a 1–5 scale, where 5 is a strong buy). The average price target is $282.54, 79.8% above the latest close of $157.14. Analysts expect earnings of −$2.98 per share for 2026, +14.3% from a year earlier. For 2027 the average estimate is $4.04 per share on revenue of $1.5 billion. Axsome Therapeutics beat the EPS estimate in 5 of the last 12 quarters.
Related: AXSM income statement, AXSM key metrics, AXSM chart. See the AXSM stock overview for the latest quote and news.
AXSM forecast FAQ
What is Axsome Therapeutics's price target?
The average analyst price target for Axsome Therapeutics is $282.54, 79.8% above the latest close of $157.14.
Is Axsome Therapeutics a buy, hold or sell?
Of 22 analysts covering Axsome Therapeutics, 18 rate it a strong buy, 3 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Axsome Therapeutics's EPS forecast?
Analysts forecast −$2.98 per share for 2026 (range −$3.79 to −$2.28); for 2027 the estimate is $4.04.
What is Axsome Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $952.6 million, growth of 49.2%; for 2027 it is $1.5 billion.
When does Axsome Therapeutics report earnings?
Axsome Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 2, 2026 before the market opens; the EPS estimate is $-0.65.
Does Axsome Therapeutics usually beat earnings estimates?
Axsome Therapeutics reported EPS at or above the analyst estimate in 5 of the last 12 quarters.